why choose us

First received: October 27, 2022

Clinical Trial: Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Myelomonocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial

Brief Summary: This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts.Blasts are immature blood cells.Decitabine is in a class of medications called hypomethylation agents.It works by helping the bone marrow produce normal blood cells and by killing abnormal…

Read more